Literature DB >> 9632776

Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1.

M S Petrovick1, S W Hiebert, A D Friedman, C J Hetherington, D G Tenen, D E Zhang.   

Abstract

Control elements of many genes are regulated by multiple activators working in concert to confer the maximal level of expression, but the mechanism of such synergy is not completely understood. The promoter of the human macrophage colony-stimulating factor (M-CSF) receptor presents an excellent model with which we can study synergistic, tissue-specific activation for two reasons. First, myeloid-specific expression of the M-CSF receptor is regulated transcriptionally by three factors which are crucial for normal hematopoiesis: PU.1, AML1, and C/EBPalpha. Second, these proteins interact in such a way as to demonstrate at least two examples of synergistic activation. We have shown that AML1 and C/EBPalpha activate the M-CSF receptor promoter in a synergistic manner. As we report here, AML1 also synergizes, and interacts physically, with PU. 1. Detailed analysis of the physical and functional interaction of AML1 with PU.1 and C/EBPalpha has revealed that the proteins contact one another through their DNA-binding domains and that AML1 exhibits cooperative DNA binding with C/EBPalpha but not with PU.1. This difference in DNA-binding abilities may explain, in part, the differences observed in synergistic activation. Furthermore, the activation domains of all three factors are required for synergistic activation, and the region of AML1 required for synergy with PU.1 is distinct from that required for synergy with C/EBPalpha. These observations present the possibility that synergistic activation is mediated by secondary proteins contacted through the activation domains of AML1, C/EBPalpha, and PU.1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632776      PMCID: PMC108976          DOI: 10.1128/MCB.18.7.3915

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  80 in total

1.  Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb.

Authors:  M Britos-Bray; A D Friedman
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.

Authors:  P Erickson; J Gao; K S Chang; T Look; E Whisenant; S Raimondi; R Lasher; J Trujillo; J Rowley; H Drabkin
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

Review 3.  Transcription factors, normal myeloid development, and leukemia.

Authors:  D G Tenen; R Hromas; J D Licht; D E Zhang
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

4.  Transcriptional activation. Something new to hang your HAT on.

Authors:  M Montminy
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

5.  Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation.

Authors:  J M Pongubala; C Van Beveren; S Nagulapalli; M J Klemsz; S R McKercher; R A Maki; M L Atchison
Journal:  Science       Date:  1993-03-12       Impact factor: 47.728

6.  Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.

Authors:  S Wang; Q Wang; B E Crute; I N Melnikova; S R Keller; N A Speck
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

7.  The activation domain of transcription factor PU.1 binds the retinoblastoma (RB) protein and the transcription factor TFIID in vitro: RB shows sequence similarity to TFIID and TFIIB.

Authors:  C Hagemeier; A J Bannister; A Cook; T Kouzarides
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

8.  Regulation of lymphoid-specific immunoglobulin mu heavy chain gene enhancer by ETS-domain proteins.

Authors:  B Nelsen; G Tian; B Erman; J Gregoire; R Maki; B Graves; R Sen
Journal:  Science       Date:  1993-07-02       Impact factor: 47.728

9.  Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells.

Authors:  P E Nisson; P C Watkins; N Sacchi
Journal:  Cancer Genet Cytogenet       Date:  1992-10-15

10.  Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations.

Authors:  J S Lai; W Herr
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

View more
  62 in total

1.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  RUNX1 regulates corepressor interactions of PU.1.

Authors:  Zhenbo Hu; Xiaorong Gu; Kristine Baraoidan; Vinzon Ibanez; Arun Sharma; ShriHari Kadkol; Reinhold Munker; Steven Ackerman; Giuseppina Nucifora; Yogen Saunthararajah
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

3.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.

Authors:  Rachit Bakshi; Mohammad Q Hassan; Jitesh Pratap; Jane B Lian; Martin A Montecino; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

4.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2.

Authors:  T L Goetz; T L Gu; N A Speck; B J Graves
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

6.  Activation of Mouse Tcrb: Uncoupling RUNX1 Function from Its Cooperative Binding with ETS1.

Authors:  Jiang-Yang Zhao; Oleg Osipovich; Olivia I Koues; Kinjal Majumder; Eugene M Oltz
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

7.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

8.  Response: the role of RUNX1 isoforms in hematopoietic commitment of human pluripotent stem cells.

Authors:  Dan Ran; Kentson Lam; Wei-Jong Shia; Miao-Chia Lo; Jun-Bao Fan; David A Knorr; Patrick I Ferrell; Zhaohui Ye; Ming Yan; Linzhao Cheng; Dan S Kaufman; Dong-Er Zhang
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113

9.  Domain analyses of the Runx1 transcription factor responsible for modulating T-cell receptor-beta/CD4 and interleukin-4/interferon-gamma expression in CD4(+) peripheral T lymphocytes.

Authors:  Ryuji Uchino
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

10.  Characterization of RNA aptamers that disrupt the RUNX1-CBFbeta/DNA complex.

Authors:  Jenny L Barton; David H J Bunka; Stuart E Knowling; Pascal Lefevre; Alan J Warren; Constanze Bonifer; Peter G Stockley
Journal:  Nucleic Acids Res       Date:  2009-09-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.